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Abstract
Background and aims: Mesalazine (5-aminosalicylic acid) is the standard first-line therapy for
mild-to-moderate ulcerative colitis. In the PINCE study, remission rates were significantly greater
with combined oral/enema vs. oral/placebo treatment at 8 weeks (64% vs. 43%, respectively;
p = 0.030). In this analysis, we explored early response, mucosal healing rates, cessation of
rectal bleeding, and quality of life in PINCE.
Methods: Patients with extensive mild-to-moderately active ulcerative colitis received 8 weeks
of oral mesalazine 4 g/day, plus 4 weeks of daily active (1 g mesalazine) or placebo enema.
Early response was assessed using the abbreviated ulcerative colitis disease activity index.
Mucosal healing was assessed by disease activity index endoscopic mucosal appearance score.
Cessation of bleeding (patient diaries), quality of life (EQ-5D), and patient acceptability
(questionnaire) were also assessed.
Results: Combined mesalazine oral/enema treatment achieved a significantly higher rate of
improvement in abbreviated ulcerative colitis disease activity index (score decrease ≥ 2) within
2 weeks, compared with oral-only treatment (p = 0.032). Bleeding ceased significantly more
quickly with combination vs. oral therapy (p = 0.003). More patients showed mucosal healing
(disease activity index endoscopic mucosal appearance score 0/1) with combination vs. oralt of Gastroenterology, Institute of Translational Medicine, University of Liverpool, Crown Street, Liverpool
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201Combined oral and rectal mesalazine for treatment of active ulcerative colitistherapy, which was significantly different between groups at week 4 (p = 0.052). Both groups
showed quality of life improvements, with a significant benefit for combination vs. oral therapy
at week 4 in multiple domains. Most patients reported finding the treatment acceptable.
Conclusions: Rapid cessation of symptoms was seen with combination therapy, which is
particularly important to patients and may improve quality of life.
© 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.1. Introduction
Mesalazine (5-aminosalicylic acid [5-ASA]) is recommended
for the treatment of most forms of mild-to-moderately
active ulcerative colitis (UC) in guidelines from the European
Crohn's and Colitis Organisation,1 reflecting the status of
mesalazine as the current standard of care for both the
induction and maintenance of remission in mild-to-moderate
UC. Nevertheless, there is scope to further optimize drug
delivery and dosing schedules, which may improve patient
adherence.2
Mesalazine has been shown to be effective when used as
either an oral therapy,3–8 a rectal therapy administered as a
suspension (enema), suppository, gel or foam,9–18 or when
oral and rectal formulations are used in combination.15,19–23
A dose-related effect has been shown for oral mesalazine
such that doses ≥2 g/day show superior efficacy compared
with lower doses,24 and 2.4–4.0 g daily oral therapy is
generally used to induce remission.22 Clinical response rates
of 60–70% and clinical remission rates of 40–70% have been
reported in various 6–8 week studies.25 However, both the
oral and the rectal routes of administration are limited in
their sites of mesalazine delivery. Oral therapy alone may
not be sufficient to achieve therapeutic response in the
distal sites of the large bowel, while mesalazine supposito-
ries and rectal suspensions do not have any effect above the
rectosigmoid junction and splenic flexure, respectively.22
Thus, combination therapy may show benefits over either
route used in isolation.
The PINCE study was a European, multicenter, random-
ized trial, comparing therapy with combined mesalazine
(PENTASA®; Ferring Pharmaceuticals, Denmark) oral (4 g/day)
plus rectal suspension (1 g/day), and mesalazine (PENTASA)
oral (4 g/day) plus placebo suspension in patients with exten-
sive mild-to-moderately active UC. Remission rates, based on
clinical and endoscopic criteria, were higher in themesalazine
combination therapy group than in the oral therapy group at
weeks 4 and 8, significantly so at week 8 (combination, 64% vs.
oral 43%, p = 0.030).22
UC treatment has several important goals in addition to
remission.25 Mucosal healing is an important outcome, and
may prevent or reduce the risk of colorectal cancer.26 Other
important outcomes from the patient's perspective include
the rapid cessation of distressing symptoms such as rectal
bleeding, an important clinical endpoint in many trials of UC
therapy. In the PINCE study, of those patients with rectal
bleeding at baseline, 73% in the mesalazine combination
therapy group, compared with 38% in the oral therapy group
achieved cessation of rectal bleeding over the 8-week
study.22 Rectal bleeding, abdominal pain, and other symp-
toms of the condition can also have a significant impact onpatient quality of life (QoL).2 In the present secondary
analysis of the PINCE study, we examined mucosal healing,
early (week 2) clinical efficacy, time to cessation of rectal
bleeding in patients with different types of bleeding at
baseline (traces, frank, or mainly blood), and QoL in patients
receiving combined or oral-only treatment.
2. Materials and methods
2.1. Patients
Patients were recruited between January 2002 and July 2003
in six European countries (France, UK, Spain, Germany, The
Netherlands, and Sweden). The study was approved by local
institutional review boards and ethics committees. Male and
female patients N18 years of age were eligible to participate
if they had previously established extensive UC with mild-
to-moderate exacerbation, and a UC disease activity index
(UCDAI) score of ≥3 and ≤8.4 All patients gave written,
informed consent prior to study entry. Exclusion criteria
included: infectious colitis; oral maintenance treatment with
total daily doses N3 g of sulfasalazine, mesalazine, or 4-ASA
within 30 days prior to study entry; any immunosuppressive
agents during the 30 days prior to study enrollment; chronic
use of nonsteroidal anti-inflammatory drugs (oral and/or
rectal routes) in the 7 days prior to inclusion (chronic use
defined as drug intake for a minimum of 7 consecutive days);
intake of corticosteroids (oral and/or rectal routes) within
7 days prior to enrollment; severe renal/hepatic impair-
ment, malignant disease, allergy to salicylates, alcoholism,
or drug addiction, or any other disease or condition that
might interfere with study assessments, as judged by the
investigator; participation in another clinical study in the
previous 30 days; women of child bearing potential who were
not using an effective method of contraception; or pregnancy
and lactation.
2.2. Study design
This was a double-blind, multinational, randomized, parallel
group, placebo-controlled, 8-week clinical study in outpa-
tients with a previously established diagnosis of extensive
mild-to-moderately active UC (macroscopic inflammation
beyond the splenic flexure during a full colonoscopy).22
Patients were randomized to receive either mesalazine
(PENTASA) enema (1 g/day [OD] in 100 ml at bedtime) or
placebo enema for a period of 4 weeks. Patients in both arms
also received oral mesalazine (PENTASA; 2 g/twice daily
[BD], granules swallowed with water or juice) for 8 weeks.
Patients, enrolled following a medical evaluation of
the initial clinical and endoscopic severity of their UC, were
202 C.S.J. Probert et al.evaluated at randomization (day 1), and at 4 weeks (±2 days)
and 8 weeks (±2 days) using the UCDAI score, which is based
on clinical signs and endoscopic evaluation of the distal co-
lon during rectosigmoidoscopy.4 Remission was defined as a
UCDAI score b2, and improvement was defined as a decrease
in UCDAI score of ≥2 points from baseline. Abbreviated
UCDAI (no sigmoidoscopy) was assessed at week 2 (±1 day).
Patients were asked to complete diaries daily with their
number of stools and assessment of rectal bleeding. Time to
cessation of rectal bleeding was evaluated based on the diary
records.
2.3. Endpoints and post-hoc analyses
All endpoints were defined prior to study start. The primary
endpoint was remission rate at 4 weeks based on the UCDAI
score. Secondary endpoints included: remission rates at
8 weeks; improvement rates at 4 and 8 weeks (UCDAI);
improvement rates at 2, 4, and 8 weeks (abbreviated UCDAI);
time to cessation of rectal bleeding; and patient QoL. Patient
QoL was assessed using the EQ-5D questionnaire at base-
line and at 2, 4, and 8 weeks.27 This QoL scale includes five
domains covering mobility, self-care, usual activity, pain/
discomfort, and anxiety/depression. Each question has three
response categories: no problem; some problem; and inabil-
ity or extreme problems. Acceptability of using an oral/
enema combination therapy was assessed at week 8; patients
were asked if they would like to take a combination therapy
in case of relapse. Post-hoc analyses were carried out to
assess differences in mucosal healing between the two
treatments, and to extend the abbreviated UCDAI analysis
at week 2.
2.4. Statistical methods
Differences in the proportion of patients between groups were
analyzed by two-sided Chi-square test. For changes from
baseline, median change was analyzed with the two-sided
Wilcoxon test, while mean change was analyzed with the
F-statistic for analysis of variance. Time to cessation of rectal
bleeding (date of cessation minus date of first intake) was
analyzed using nonparametric Kaplan–Meier methodology.
Differences between groups were analyzed using a two-sided
log-rank test. The significance of the median change from
baseline in mucosal score was based on nonparametric testing
of distributions in the intent-to-treat (ITT) population.
3. Results
In total, 127 patients at 43 centers in six countries were
randomized to receive 2 g oral mesalazine (PENTASA) BD plusTable 1 Change under treatment in abbreviated UCDAI at 2 wee
Abbreviated UCDAI at 2 weeks
Median change from baseline (p = 0.030, Wilcoxon test; two-sided
Mean change from baseline (p = 0.053, F-statistic for analysis of v
Percent improved (95% confidence interval) (p = 0.032, chi-squareeither 1 g mesalazine (PENTASA) enema (n = 71) or placebo
enema (n = 56) OD. As reported previously,22 baseline demo-
graphics were well balanced between groups. Of the 116 ITT
patients, 63 were in the active enema group and 53 in
the placebo enema group. Of these, 71 patients (42 and
29, respectively) constituted the per-protocol population
(i.e. no protocol violations).
3.1. Remission and improvement: early response
After only 2 weeks, the rates of remission (abbreviated
UCDAI b 2) were 33% for the combination therapy group
compared with 30% for the oral therapy group.28 Furthermore,
improvement (abbreviated UCDAI decrease ≥ 2) was seen in
N30% of patients in both arms. Improvement rates compared
with baseline (abbreviated UCDAI decrease ≥ 2) were signif-
icantly higher in the combination therapy group than the oral
therapy group at week 2 (65% vs. 45%; p = 0.032; Table 1),
week 4 (89% vs. 62%; p = 0.001), and week 8 (86% vs. 68%;
p = 0.026). Results of the logistic regression analyses for
the ITT population confirmed that patients receiving combi-
nation therapy were more likely to have improvement than
patients receiving oral therapy at week 4 (odds ratio 6.560;
p = 0.002) and week 8 (odds ratio 3.578; p = 0.027). A median
change of −2 in abbreviated UCDAI at week 2 was seen in the
combination therapy group compared with −1 in the oral
therapy group (Table 1); a difference that was statisti-
cally significant (p = 0.030). Remission rates (UCDAI b 2) in
the ITT population were numerically higher in the combination
therapy group comparedwith the oral therapy group atweek 4
(44% vs. 34%), and significantly higher at week 8 (64% vs. 43%;
p = 0.030).
3.2. Mucosal healing
Mucosal healing was evident in both treatment groups
(Table 2), and there was a trend for more patients to achieve
mucosal healing with combined vs. oral therapy. In the com-
bination therapy group, 95% of patients had a mucosal score
(disease activity index endoscopic mucosal appearance score)
of 0 or 1 at week 4 compared with 83% of patients in the oral
therapy group (ITT population, p = 0.052). The mean change
from baseline in mucosal score was −1.09 (combination
therapy group) vs. −0.60 (oral therapy group; p = 0.006) at
week 4 and −1.10 (combination therapy group) vs. −0.66 (oral
therapy group; p = 0.024) at week 8.
3.3. Rectal bleeding
The time to the cessation of rectal bleeding in patients with
baseline rectal bleeding and with cessation of rectal bleedingks (ITT population).
Mesalazine oral + active
enema (n = 63)
Mesalazine oral + placebo
enema (n = 53)
) −2.00 −1.00
ariance) −2.44 −1.64
test) 65 (53–77) 45 (32–59)
Table 2 Mucosal healing from baseline to week 8 with
mesalazine oral plus active enema (combination therapy) and
mesalazine oral plus placebo enema (oral therapy) in the PINCE
study (ITT population, observed cases).
Time point Mucosal
score a
Mesalazine
oral + active
enema, % (n)
Mesalazine
oral + placebo
enema, % (n)
Baseline† 0 0 (0) 0 (0)
1 32 (20) 43 (23)
0 or 1 32 (20) 43 (23)
2 or 3 68 (43) 57 (30)
p value ‡ 0.196
Week 4¶ 0 37 (21) 23 (11)
1 58 (33) 60 (28)
0 or 1 95 (54) 83 (39)
2 or 3 5 (3) 17 (8)
p value ‡ 0.052
Week 8§ 0 50 (29) 38 (18)
1 36 (21) 38 (18)
0 or 1 86 (50) 77 (36)
2 or 3 14 (8) 23 (11)
p value ‡ 0.203
For the combination vs. oral therapy groups, respectively: †n = 63
and n = 53; ¶n = 57 and n = 47; §n = 58 and n = 47.
a Disease activity index endoscopic mucosal appearance score:
0 = normal; 1 = erythema, reduced capillary network, mild
friability, minimal granularity; 2 = friability, marked erythema,
no vascularization, erosions, pus; 3 = ulceration, spontaneous
bleeding, pus.
‡ p value based on chi-square test of the difference between
treatment arms in the proportion of patients with a score of 0/1 or
2/3.
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bleeding ceased, the mean duration of rectal bleeding was
21.0 days (standard deviation [SD] 18.4) in the combination
treatment group compared with 24.4 days (SD 21.0) in the
oral therapy group. Bleeding stopped within 7 days of the
start of the study for 35% of patients in the combination
therapy group and 25% of those in the oral therapy group.
Kaplan–Meier methodology showed that the time to cease
rectal bleeding was significantly shorter for patients in theTable 3 Cessation of rectal bleeding among patients with
rectal bleeding at baseline and with cessation of rectal
bleeding during the study (ITT population).
Mesalazine
treatment
Baseline score Mean time to
cessation,
days (range)
Oral + active enema All patients 21.0 (0–53)
Traces of blood 18.4 (0–51)
Frank blood 20.5 (0–53)
Mainly blood 31.5 (1–46)
Oral + placebo enema All patients 24.4 (1–63)
Traces of blood 21.3 (1–51)
Frank blood 18.9 (3–49)
Mainly blood 54.5 (46–63)combination therapy group compared with oral therapy, with
a median of 28 days vs. N56 days, respectively (log-rank
p value 0.003, Fig. 1). The time taken to cease rectal bleed-
ing in all patients with frank blood at baseline (irrespective of
achieving cessation of rectal bleeding during the study) was
also shorter in patients treated with the combination vs. oral
therapy (median 21 days vs. N56 days, respectively; log-rank
p value 0.003).
3.4. Quality of life and treatment acceptability
The proportion of patients who reported ‘some problem’ in
any domain fell in both treatment groups from baseline to
week 8 with no major differences between the treatment
groups (Table 4). However, results show a trend for more
rapid effects in the combination therapy group in several
domains. In the mobility domain, the proportion of patients
with ‘some problems’ at week 4 in the combination therapy
group decreased to a greater extent than that in the oral
therapy group; this was a small but significant improvement
(p = 0.049). Also at week 4, there was a significant improve-
ment in the ‘usual activity’ domain (p = 0.034), a trend
towards improved pain/discomfort (p = 0.053), and a signif-
icant improvement in anxiety/depression (p = 0.049) in the
combination therapy group compared with the oral therapy
group.
Of 114 patients asked if they were prepared to take a
combination therapy in the future, 51 patients (84%) from
the combination therapy group and 45 patients (85%) from
the oral therapy group responded positively.
4. Discussion
The PINCE study showed that adding a mesalazine enema to
an oral mesalazine regimen provides additional benefit for
patients with extensive mild-to-moderately active UC defined
by involvement beyond the splenic flexure.22 Although the
PINCE trial did not reach its primary endpoint of showing a
higher remission rate at 4 weeks for the combination therapy
group, secondary endpoints were met, including remission at
8 weeks.22 As enema therapy was given only until week 4, this
result may indicate a delayed treatment effect. In the present
analyses, we demonstrate several earlier efficacy benefits
for the combination therapy compared with the oral therapy
alone. These comprise 2-week UC improvement based on
decreased abbreviated UCDAI score, increased mucosal
healing from 4 weeks onwards, reduced time to cessation of
rectal bleeding, and improved QoL in several domains.
At just 2 weeks after starting treatment, 26% more pa-
tients had achieved an improvement from baseline (≥2
decrease in abbreviated UCDAI) with combination vs. oral
therapy alone (p = 0.032), emphasizing the rapidity of
response achieved with combination therapy in this patient
population. Data from PINCE also show a trend for more
patients to go on to achieve endoscopic remission with
combination therapy compared with oral therapy, with 50%
and 38% of patients, respectively, achieving a mucosal score
of 0 at week 8, vs. 0% at baseline (Table 2). Indeed, the effect
on mucosal score was significantly greater for the combi-
nation therapy from 4 weeks onwards. This reflects the
extensive UC in the study population: the patients in PINCE
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Figure 1 Time to cessation of rectal bleeding in all patients with rectal bleeding at baseline in the PINCE study. Note: All patients
without cessation of rectal bleeding until day 56 or until premature withdrawal are censored. Circles mark censored patients with
number of patients censored. Data includes patients who had prematurely withdrawn, i.e., for whom no information is available.
Table 4 QoL assessments at baseline, week 2, week 4, and week 8 in the PINCE study. The p values indicate a difference in the
rate of improvement from baseline (week 0) to week 4 for the combination therapy group compared with the oral therapy group.
QoL measurement Mesalazine treatment Week Total, n No problems,
n (%)
Some problems,
n (%)
Inability or extreme
problems, n (%)
Mobility Oral + active enema 0 62 54 (87) 8 (13) 0 (0)
2 61 57 (93) 4 (7) 0 (0)
4 58 57 (98) 1 (2) ⁎ 0 (0)
8 57 55 (97) 2 (4) 0 (0)
Oral + placebo enema 0 53 49 (93) 4 (8) 0 (0)
2 53 47 (89) 5 (9) 1 (2)
4 49 45 (92) 4 (8) ⁎ 0 (0)
8 40 39 (98) 1 (3) 0 (0)
Usual activity Oral + active enema 0 62 44 (71) 18 (29) 0 (0)
2 61 44 (72) 17 (28) 0 (0)
4 58 51 (88) 7 (12) ⁎⁎ 0 (0)
8 57 53 (93) 4 (7) 0 (0)
Oral + placebo enema 0 53 28 (53) 25 (47) 0 (0)
2 53 38 (72) 15 (28) 0 (0)
4 49 34 (69) 15 (31) ⁎⁎ 0 (0)
8 40 35 (88) 5 (13) 0 (0)
Pain/discomfort Oral + active enema 0 62 17 (27) 44 (71) 1 (2)
2 61 36 (59) 24 (39) 1 (2)
4 58 46 (79) 11 (19) † 1 (2)
8 57 47 (83) 9 (16) 1 (2)
Oral + placebo enema 0 53 17 (32) 34 (64) 2 (4)
2 53 30 (57) 23 (43) 0 (0)
4 49 32 (65) 17 (35) † 0 (0)
8 40 34 (85) 6 (15) 0 (0)
Anxiety/depression Oral + active enema 0 62 42 (68) 18 (29) 2 (3)
2 60 45 (75) 15 (25) 0 (0)
4 58 49 (85) 9 (16) ⁎⁎⁎ 0 (0)
8 57 48 (84) 9 (16) 0 (0)
Oral + placebo enema 0 53 24 (45) 29 (55) 0 (0)
2 53 35 (66) 17 (32) 1 (2)
4 49 31 (63) 17 (35) ⁎⁎⁎ 1 (2)
8 40 28 (70) 11 (28) 1 (3)
⁎ p = 0.049.
⁎⁎ p = 0.034.
⁎⁎⁎ p = 0.049.
† p = 0.053.
204 C.S.J. Probert et al.
205Combined oral and rectal mesalazine for treatment of active ulcerative colitishad more extensive disease than in many other studies; the
results with the combination therapy may therefore indi-
cate greater efficacy in such patients. As the majority of
clinical symptoms in extensive UC probably relate to disease
activity in the distal part of the colon, treatments that
target the distal colon are more likely to show rapid cessation
of symptoms, leading to subsequent clinical remission.29
Combination therapy has previously been shown to be
significantly better at stopping rectal bleeding than rectal
suspension or oral therapy alone, with a mean time to
cessation of bleeding of 11.9, 24.8, and 25.5 days, respec-
tively.15 Furthermore, a recent analysis found that this
differential effect on rectal bleeding may occur from as
early as day 8 of treatment onwards, with clinical remission
at week 3 also significantly more frequent in those who
received combination vs. oral therapy.30 These data are
consistent with the 2-week improvement seen in the present
study, suggesting that earlier cessation of rectal bleeding
may translate into earlier mucosal healing in patients with
extensive mild-to-moderately active UC. Oral formulations
that enable delivery throughout the whole colon are likely to
best complement a combination therapy regimen.
The rapid cessation of symptoms, seen at 2 weeks in the
PINCE study seem to have a profound effect on QoL and may
promote an increase in patient adherence to medication. In
the wide treatment of UC, it is important to acknowledge
that while more than 90% of patients in clinical studies are
compliant, only 40% of patients in everyday life take their
prescribed therapy.31 It is encouraging that the majority of
patients in the combination therapy group stated that they
would be willing to take combination rectal suspension and
oral therapy in the future.
For extensive mild-to-moderately active UC, data from
the PINCE study suggest that combination therapy could be
more effective than either oral or topical treatment used in
isolation. While some level of dose proportionality has been
observed with mesalazine treatment,24 it seems unlikely
that the results seen here are simply a result of a short-term
increase in dosage. This is particularly true for patients with
extensive disease, for whom an increase in dosage of a
topical therapy alone is unlikely to outweigh the challenges
of successful oral drug delivery to the distal colon and
topical administration above the rectosigmoid junction and
splenic flexure. However, it is also worth considering that in
contrast to treatment for induction of remission, doses in
the maintenance setting are often substantially less.25,32
Consideration of dose proportionality at this low end of the
dose spectrum may indeed yield benefits in the long-term
management of patients with UC and may be a suitable topic
for further investigation.
Overall, our results provide further evidence that com-
bination therapy improves the rate of mucosal healing and
reduces the time taken to cease rectal bleeding compared
with oral mesalazine alone. The rapid cessation of symptoms
is of particular importance to patients, as a shorter time
period from initiation of treatment to noticeable alleviation
of symptoms has a direct impact on their QoL. The data also
strengthen current guideline recommendations, which ad-
vocate the first-line use of combination therapy for patients
with extensive, mild-to-moderately active UC.1 Although it
is common practice to introduce oral steroids at an early
stage in the hope of a rapid response,33 our data indicate thatrapid improvements in UC symptoms can also be achieved by
adding a mesalazine enema to an oral mesalazine regimen.
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